Welcome to our dedicated page for Biogen SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biogen Inc. (BIIB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other key documents. As a Nasdaq-listed biotechnology company, Biogen uses these filings to report financial results, material events and governance matters that are important for investors evaluating its activities in neurology, rare diseases and immunology.
Recent Form 8-K filings show how Biogen communicates results of operations and financial condition, including quarterly earnings press releases and preliminary estimates of acquired in-process research and development, upfront and milestone expenses. The company explains that these expenses arise from collaboration and license agreements and are presented as a separate line item in its condensed consolidated statements of income. Other 8-K filings cover shareholder votes at the annual meeting, such as the election of directors and ratification of the independent registered public accounting firm.
Through this page, users can review Biogen’s SEC-reported information alongside Stock Titan’s AI-powered tools, which can help summarize lengthy filings and highlight key items such as collaboration-related charges, capital allocation decisions and governance outcomes. Investors interested in Biogen’s partnerships, pipeline investments and financial reporting practices can use these filings to understand how the company accounts for its research collaborations, including those involving antisense oligonucleotides, monoclonal antibodies and emerging modalities.
In addition to 8-Ks, this page can link to other Biogen filings available on EDGAR, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company provides more detailed discussion of its business, risk factors and financial statements. Together, these documents form the regulatory record that underpins fundamental analysis of BIIB.
Biogen Inc. reported that its Chief Legal Officer, Susan H. Alexander, will leave the company effective at the end of May 2026. The company has started a search for her successor to lead its legal function. Other aspects of Biogen’s operations are not discussed in this report.
Viehbacher Christopher reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that President and CEO Christopher Viehbacher received a grant of 38,015 restricted stock units on February 13, 2026. These units are a form of equity compensation and were awarded at a stated price of $0.00 per unit.
The restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the grant date of February 13, 2026. This means the award is structured to vest over three years, aligning the CEO’s compensation with longer-term company performance.
Singhal Priya reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that Priya Singhal, Head of Development, received a grant of 10,560 restricted stock units. These RSUs were awarded at no cash cost per unit as part of equity compensation. According to the disclosure, the units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date.
BIOGEN INC. executive Nicole Murphy reported a grant of 10,560 restricted stock units and a small open-market share purchase. The restricted stock units were awarded on February 13, 2026 and vest in three equal yearly installments starting on the first anniversary of that grant date. On February 12, 2026 she bought 3 shares of Biogen common stock in an open-market transaction at a price of $195.035 per share. Following these transactions, her direct holdings total 19,611.0408 shares of common stock and 10,560 restricted stock units.
Biogen Inc. reported that Chief Financial Officer Robin Kramer acquired 8,450 restricted stock units as a grant on February 13, 2026. The RSUs were awarded at a price of $0.00 per unit, reflecting equity-based compensation rather than an open-market purchase.
According to the footnote, these restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the grant date of February 13, 2026. After this grant, Kramer directly holds 8,450 RSUs, which may convert into Biogen shares as they vest.
Keeney Adam reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. executive Adam Keeney, Head of Corporate Development, reported an award of 8,025 restricted stock units. These RSUs were granted at no purchase price and represent the right to receive Biogen common shares upon vesting. The units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date.
Izzar Rachid reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. executive Rachid Izzar, Head of Global Product Strategy, received a grant of 7,390 restricted stock units. These RSUs were awarded at no cash cost per unit and represent a form of stock-based compensation that aligns the executive’s interests with shareholders.
The restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the February 13, 2026 grant date. The entire 7,390-unit award is reported as directly owned following the transaction.
Grogan Jane reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that Head of Research Jane Grogan received a grant of 8,450 restricted stock units (RSUs) on February 13, 2026. These RSUs vest in three equal yearly installments, beginning on the first anniversary of the grant date, providing her with long-term, equity-based compensation rather than an open-market share purchase or sale.
Gregory Ginger reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. executive Gregory Ginger, EVP of Human Resources, received an equity grant of 8,025 restricted stock units on February 13, 2026. These RSUs were awarded at no cash cost to him as part of his compensation and represent a right to receive Biogen shares in the future.
The 8,025 restricted stock units vest in three equal yearly installments, beginning on the first anniversary of the February 13, 2026 grant date. All units are reported as directly owned following the grant, meaning his reported derivative holdings increased by the full award amount.
Godbout Sean reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. Chief Accounting Officer Sean Godbout reported receiving a grant of 1,800 restricted stock units. These RSUs were awarded at a stated price of $0.00 per unit and increase his directly owned derivative holdings to 1,800 units. According to the footnote, the award vests in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026, meaning one-third of the units will vest each year over a three-year period.